Phase I/II study of Y-90-clivatuzumab tetraxetan (Y-90-hPAM4) combined with gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results. Conference

Ocean, Allyson J, Guarino, Michael J, Pennington, Kenneth L et al. (2012). Phase I/II study of Y-90-clivatuzumab tetraxetan (Y-90-hPAM4) combined with gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results. . JOURNAL OF CLINICAL ONCOLOGY, 30(15),

cited authors

  • Ocean, Allyson J; Guarino, Michael J; Pennington, Kenneth L; Springett, Gregory M; Gulec, Seza A; Bekaii-Saab, Tanios S; Montero, Alberto J; Mitchell, Edith P; Kauh, John S; Sung, Max W; Gold, David V; Horne, Heather; Wegener, William A; Goldenberg, David M

authors

date/time interval

  • June 1, 2012 -

publication date

  • May 20, 2012

webpage

published in

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

Location

  • Chicago, IL

Conference

  • 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

publisher

  • AMER SOC CLINICAL ONCOLOGY

volume

  • 30

issue

  • 15